Advances in Therapy

, Volume 27, Issue 6, pp 381–399 | Cite as

Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain

  • Bernd Lange
  • Brigitte Kuperwasser
  • Akiko Okamoto
  • Achim Steup
  • Thomas Häufel
  • Judy Ashworth
  • Mila Etropolski
Original Research



This pooled analysis of data from three phase 3 studies in patients with chronic osteoarthritis knee or low back pain evaluated the efficacy and tolerability of tapentadol prolonged release (PR; 100–250 mg twice daily) compared with placebo and oxycodone hydrochloride (HCl) controlled release (CR; 20–50 mg twice daily).


Patients in each study were randomized to receive twice-daily doses of placebo, tapentadol PR (100–250 mg), or oxycodone HCl CR (20–50 mg) for a 12-week maintenance period, preceded by a 3-week titration period. Primary endpoints were change from baseline in average pain intensity (11-point numeric rating scale) at week 12 of the maintenance period and for the overall maintenance period using last observation carried forward for imputation of values missing after treatment discontinuation.


A total of 2968 patients were evaluated for efficacy; 2974 patients were evaluated for safety. Compared with placebo, treatment with tapentadol PR or oxycodone CR resulted in significantly greater reductions in pain intensity from baseline at week 12 and for the overall maintenance period (all P<0.001). For both primary endpoints, the efficacy of tapentadol PR was noninferior to oxycodone CR (P<0.001), and tapentadol PR had superior gastrointestinal tolerability compared with oxycodone CR (P<0.001). Results of analyses of responders, patient global impression of change, Short Form-36 domains (except general health), and the EuroQol 5-Dimension health status index were significantly better for tapentadol PR than oxycodone CR (all P≤0.048); these results may have been affected by the worse tolerability profile of oxycodone CR. A higher percentage of patients discontinued treatment with oxycodone CR (61.7% [616/999]) compared with tapentadol PR (43.5% [425/978]).


Tapentadol PR (100-250 mg twice daily) was efficacious and provided efficacy that was similar to oxycodone HCl CR (20–50 mg twice daily) for the management of chronic osteoarthritis knee and low back pain, with a superior gastrointestinal tolerability profile and fewer treatment discontinuations.


chronic pain EQ-5D low back pain opioid responder rates opioid tolerability osteoarthritis oxycodone controlled release quality of life tapentadol prolonged release SF-36 treatment discontinuation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain. 1999;15:179–183.CrossRefPubMedGoogle Scholar
  2. 2.
    Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain. 2005;6:21–28.CrossRefPubMedGoogle Scholar
  3. 3.
    Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin. 2007;23:117–128.CrossRefPubMedGoogle Scholar
  4. 4.
    Portenoy RK, Farrar JT, Backonja MM, et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain. 2007;23:287–299.CrossRefPubMedGoogle Scholar
  5. 5.
    Rauck RL, Bookbinder SA, Bunker TR, et al. The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag. 2006;2:155–166.PubMedGoogle Scholar
  6. 6.
    Hale M, Tudor IC, Khanna S, Thipphawong J. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther. 2007;29:874–888.CrossRefPubMedGoogle Scholar
  7. 7.
    Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med. 2005;6:357–366.CrossRefPubMedGoogle Scholar
  8. 8.
    Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med. 2000;160:853–860.CrossRefPubMedGoogle Scholar
  9. 9.
    Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372–380.CrossRefPubMedGoogle Scholar
  10. 10.
    Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11(Suppl.):S105–S120.PubMedGoogle Scholar
  11. 11.
    Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10:35–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Tzschentke TM, Christoph T, Kogel B, et al. (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323:265–276.CrossRefPubMedGoogle Scholar
  13. 13.
    Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol HCl. Drugs Future. 2006;31:1053–1061.CrossRefGoogle Scholar
  14. 14.
    Afilalo M, Kuperwasser B, Kelly K, et al. Efficacy and safety of tapentadol extended release (ER) for chronic pain due to osteoarthritis of the knee: results of a phase 3 study. Pain Pract. 2009;9:159.Google Scholar
  15. 15.
    Buynak R, Shapiro D, Okamoto A, Lange C, Etropolski M. Efficacy, safety, and gastrointestinal tolerability of tapentadol ER in a randomized, double-blind, placebo- and active-controlled phase III study of patients with chronic low back pain. J Pain. 2009;10:S48.CrossRefGoogle Scholar
  16. 16.
    Ware JE, Jr., Donald Sherbourne C. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483.CrossRefPubMedGoogle Scholar
  17. 17.
    The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.CrossRefGoogle Scholar
  18. 18.
    Hauschke D, Pigeot I. Establishing efficacy of a new experimental treatment in the ‘gold standard’ design. Biom J. 2005;47:782–786.CrossRefPubMedGoogle Scholar
  19. 19.
    Wild JE, Grond S, Kuperwasser B, et al. Longterm safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. In press.Google Scholar
  20. 20.
    Markenson JA, Croft J, Zhang PG, Richards P. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain. 2005;21:524–535.CrossRefPubMedGoogle Scholar
  21. 21.
    Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol. 1999;26:862–869.PubMedGoogle Scholar
  22. 22.
    Purdue Pharma. Oxycontin® (oxycodone HCl controlled-release) product. Stamford, CT: Purdue Pharma L.P.; 2007.Google Scholar

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  • Bernd Lange
    • 1
  • Brigitte Kuperwasser
    • 2
  • Akiko Okamoto
    • 2
  • Achim Steup
    • 1
  • Thomas Häufel
    • 1
  • Judy Ashworth
    • 1
  • Mila Etropolski
    • 2
  1. 1.Global Development, Grünenthal GmbHAachenGermany
  2. 2.Johnson & Johnson Pharmaceutical Research & DevelopmentTitusvilleUSA

Personalised recommendations